Quantbot Technologies LP Grows Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Quantbot Technologies LP grew its stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 102.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 39,019 shares of the company's stock after purchasing an additional 19,742 shares during the period. Quantbot Technologies LP owned approximately 0.07% of PROCEPT BioRobotics worth $3,142,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of PRCT. Swiss National Bank grew its stake in shares of PROCEPT BioRobotics by 5.8% during the third quarter. Swiss National Bank now owns 95,400 shares of the company's stock valued at $7,643,000 after purchasing an additional 5,200 shares during the last quarter. Avior Wealth Management LLC lifted its holdings in PROCEPT BioRobotics by 6,823.1% during the 3rd quarter. Avior Wealth Management LLC now owns 3,600 shares of the company's stock worth $288,000 after buying an additional 3,548 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in PROCEPT BioRobotics in the 3rd quarter valued at $1,371,000. Advisors Asset Management Inc. boosted its holdings in PROCEPT BioRobotics by 28.8% in the third quarter. Advisors Asset Management Inc. now owns 12,350 shares of the company's stock valued at $989,000 after acquiring an additional 2,758 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new stake in shares of PROCEPT BioRobotics during the 3rd quarter worth approximately $979,000. 89.46% of the stock is owned by institutional investors and hedge funds.

PROCEPT BioRobotics Trading Up 2.0 %

Shares of NASDAQ:PRCT traded up $1.25 during mid-day trading on Tuesday, hitting $62.15. The company had a trading volume of 848,785 shares, compared to its average volume of 727,428. The company has a market capitalization of $3.41 billion, a PE ratio of -31.87 and a beta of 1.05. PROCEPT BioRobotics Co. has a one year low of $45.56 and a one year high of $103.81. The firm has a fifty day moving average price of $66.71 and a 200 day moving average price of $78.25. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07.

Remove Ads

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). The business had revenue of $68.24 million for the quarter, compared to analysts' expectations of $66.79 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. As a group, research analysts forecast that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on PRCT shares. Wells Fargo & Company reissued an "overweight" rating and set a $112.00 price target on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. Morgan Stanley decreased their target price on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Finally, Truist Financial reissued a "buy" rating and issued a $90.00 price objective (down previously from $105.00) on shares of PROCEPT BioRobotics in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $94.29.

Insider Transactions at PROCEPT BioRobotics

In related news, CEO Reza Zadno sold 5,475 shares of PROCEPT BioRobotics stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $312,403.50. Following the sale, the chief executive officer now owns 173,070 shares in the company, valued at $9,875,374.20. The trade was a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Kevin Waters sold 733 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $41,824.98. Following the transaction, the chief financial officer now owns 107,991 shares in the company, valued at $6,161,966.46. This trade represents a 0.67 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 6,455 shares of company stock valued at $368,322. 17.40% of the stock is currently owned by company insiders.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).